Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | COVID-19 Vaccination | Research

COVID-19 vaccination side effects among the child age group: a large cross-sectional online based survey in Saudi Arabia

Authors: Hassan Alwafi, Abdallah Y. Naser, Abdulelah M. Aldhahir, Ahmad Alhazmi, Areen Naif Alosaimi, Rasha Abdulaziz Mandili, Zaid Majeed, Emad Salawati, Rakan Ekram, Mohammed Samannodi, Hamza Assaggaf, Mohammed Almatrafi, Jaber S. Alqahtani, Safaa Mohammed Alsanosi, Faisal Minshawi

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Multiple vaccines have been tested in clinical trials for their efficacy and safety. In Saudi Arabia, Pfizer–BioNTech or Moderna were approved for children, however, previous studies to report their safety profile are limited. This research aims to understand the side effect of children's vaccination against SARS-CoV-2 infection in Saudi Arabia.

Methods

This was an observational retrospective cross-sectional study was conducted using an online survey in Saudi Arabia from March to May 2022. The inclusion criteria were parents aged 18 years and above who live in Saudi Arabia and have vaccinated their children. The self-reported questionnaire was adopted from published studies to investigate the study objectives Descriptive statistics were used to describe patients’ demographic characteristics, continuous data were reported as mean ± S.D., categorical data were reported as percentages (frequencies), and logistic regression was used to identify predictors of persistent post-COVID-19 symptoms.

Results

This study had a total of 4,069 participants. Only 41.9% of the participants reported that their child(ren) had been infected with the coronavirus. 2.00 was the median number of children (IQR: 1.00–4.00). More than half of the study participants (64.2%) reported that a family member had been infected with the coronavirus. Both parents received COVID-19 vaccination, according to most participants (88.7%). Most participants (70.5%) stated that all children who met the vaccination criteria had received the vaccine. Most participants (83.5%) said their child or children had two doses of their vaccine, and about half (50.4%) of those who received the vaccine reported experiencing side effects. In addition, the majority (78.9%) reported that the side effects appeared within one day of receiving the vaccine, and nearly two-thirds (65.7%) reported that the side effects lasted between one and three. A total of 11,831 side effects cases were documented. Pain at the injection site, hyperthermia, and fatigue were the most reported side effects, accounting for 15.3%, 14.1%, and 13.2%, respectively.

Conclusion

It appears that the side effects of the COVID-19 vaccine for children are minor, tolerable, and like those described previously in clinical trials. Our data should encourage the public about the safety of receiving the COVID-19 vaccine for children.
Literature
2.
go back to reference Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60.
3.
go back to reference Sanyaolu A, et al. Global pandemicity of COVID-19: situation report as of June 9, 2020. Infect Dis (Auckl). 2021;14:1178633721991260.CrossRef Sanyaolu A, et al. Global pandemicity of COVID-19: situation report as of June 9, 2020. Infect Dis (Auckl). 2021;14:1178633721991260.CrossRef
5.
go back to reference Alrashed S, et al. Impact of lockdowns on the spread of COVID-19 in Saudi Arabia. Inform Med Unlocked. 2020;20: 100420.CrossRef Alrashed S, et al. Impact of lockdowns on the spread of COVID-19 in Saudi Arabia. Inform Med Unlocked. 2020;20: 100420.CrossRef
6.
go back to reference Niu Y, Xu F. Deciphering the power of isolation in controlling COVID-19 outbreaks. Lancet Glob Health. 2020;8(4):e452–3.CrossRef Niu Y, Xu F. Deciphering the power of isolation in controlling COVID-19 outbreaks. Lancet Glob Health. 2020;8(4):e452–3.CrossRef
7.
go back to reference Vasireddy D, et al. Review of COVID-19 vaccines approved in the United States of America for emergency use. J Clin Med Res. 2021;13(4):204–13.CrossRef Vasireddy D, et al. Review of COVID-19 vaccines approved in the United States of America for emergency use. J Clin Med Res. 2021;13(4):204–13.CrossRef
8.
go back to reference Jamkhande A, et al. A review of approved COVID-19 vaccines. Rocz Panstw Zakl Hig. 2021;72(3):245–52. Jamkhande A, et al. A review of approved COVID-19 vaccines. Rocz Panstw Zakl Hig. 2021;72(3):245–52.
9.
go back to reference Bartsch SM, et al. The benefits of vaccinating with the first available COVID-19 Coronavirus vaccine. Am J Prev Med. 2021;60(5):605–13.CrossRef Bartsch SM, et al. The benefits of vaccinating with the first available COVID-19 Coronavirus vaccine. Am J Prev Med. 2021;60(5):605–13.CrossRef
10.
go back to reference Samannodi M, et al. Assessment of caregiver willingness to vaccinate their children against COVID-19 in Saudi Arabia: a cross-sectional study. Hum Vaccin Immunother. 2021;17(12):4857–64.CrossRef Samannodi M, et al. Assessment of caregiver willingness to vaccinate their children against COVID-19 in Saudi Arabia: a cross-sectional study. Hum Vaccin Immunother. 2021;17(12):4857–64.CrossRef
11.
go back to reference Sharma O, et al. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11: 585354.CrossRef Sharma O, et al. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11: 585354.CrossRef
12.
go back to reference Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81(4):495–501.CrossRef Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81(4):495–501.CrossRef
14.
go back to reference Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef
15.
go back to reference Walter EB, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35–46.CrossRef Walter EB, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35–46.CrossRef
16.
go back to reference Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef
18.
go back to reference Alqahtani JS, et al. Sleep quality, insomnia, anxiety, fatigue, stress, memory and active coping during the COVID-19 pandemic. Int J Environ Res Public Health. 2022;19(9):4940.CrossRef Alqahtani JS, et al. Sleep quality, insomnia, anxiety, fatigue, stress, memory and active coping during the COVID-19 pandemic. Int J Environ Res Public Health. 2022;19(9):4940.CrossRef
19.
go back to reference Alwafi H, et al. Predictors of length of hospital stay, mortality, and outcomes among hospitalised COVID-19 patients in Saudi Arabia: a cross-sectional study. J Multidiscip Healthc. 2021;14:839–52.CrossRef Alwafi H, et al. Predictors of length of hospital stay, mortality, and outcomes among hospitalised COVID-19 patients in Saudi Arabia: a cross-sectional study. J Multidiscip Healthc. 2021;14:839–52.CrossRef
20.
go back to reference Alwafi H, et al. Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to different therapeutic interventions. Cureus. 2022;14(1): e21442. Alwafi H, et al. Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to different therapeutic interventions. Cureus. 2022;14(1): e21442.
21.
go back to reference Alyami HS, et al. Depression and anxiety during the COVID-19 pandemic in Saudi Arabia: a cross-sectional study. Int J Clin Pract. 2021;75(7): e14244.CrossRef Alyami HS, et al. Depression and anxiety during the COVID-19 pandemic in Saudi Arabia: a cross-sectional study. Int J Clin Pract. 2021;75(7): e14244.CrossRef
22.
go back to reference Alyami MH, et al. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an ecological study. Front Public Health. 2020;8:506.CrossRef Alyami MH, et al. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an ecological study. Front Public Health. 2020;8:506.CrossRef
23.
go back to reference Badr OI, et al. Incidence and outcomes of pulmonary embolism among hospitalized COVID-19 patients. Int J Environ Res Public Health. 2021;18(14):7645.CrossRef Badr OI, et al. Incidence and outcomes of pulmonary embolism among hospitalized COVID-19 patients. Int J Environ Res Public Health. 2021;18(14):7645.CrossRef
24.
go back to reference Naser AY, et al. Knowledge and practices during the COVID-19 outbreak in the Middle East: a cross-sectional study. Int J Environ Res Public Health. 2021;18(9):4699.CrossRef Naser AY, et al. Knowledge and practices during the COVID-19 outbreak in the Middle East: a cross-sectional study. Int J Environ Res Public Health. 2021;18(9):4699.CrossRef
25.
go back to reference Shabrawishi M, et al. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. PLoS ONE. 2020;15(8): e0237130.CrossRef Shabrawishi M, et al. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. PLoS ONE. 2020;15(8): e0237130.CrossRef
26.
go back to reference Samannodi M, et al. Determinants of Post-COVID-19 conditions among SARS-CoV-2-infected patients in Saudi Arabia: a web-based cross-sectional study. Diseases. 2022;10(3):55.CrossRef Samannodi M, et al. Determinants of Post-COVID-19 conditions among SARS-CoV-2-infected patients in Saudi Arabia: a web-based cross-sectional study. Diseases. 2022;10(3):55.CrossRef
27.
go back to reference Aldhahir AM, et al. Physicians’ attitudes, beliefs and barriers to a pulmonary rehabilitation for COPD patients in Saudi Arabia: a cross-sectional study. Healthcare (Basel). 2022;10(5):904.CrossRef Aldhahir AM, et al. Physicians’ attitudes, beliefs and barriers to a pulmonary rehabilitation for COPD patients in Saudi Arabia: a cross-sectional study. Healthcare (Basel). 2022;10(5):904.CrossRef
28.
go back to reference Alamer E, et al. Side Effects of COVID-19 Pfizer–BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia. Vaccines. 2021;9(11):1297.CrossRef Alamer E, et al. Side Effects of COVID-19 Pfizer–BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia. Vaccines. 2021;9(11):1297.CrossRef
29.
go back to reference Alhazmi A, et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.CrossRef Alhazmi A, et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.CrossRef
30.
go back to reference Klugar M, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers. Biology. 2021;10(8):752.CrossRef Klugar M, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers. Biology. 2021;10(8):752.CrossRef
31.
go back to reference Naing NN. Determination of sample size. Malays J Med Sci. 2003;10(2):84–6. Naing NN. Determination of sample size. Malays J Med Sci. 2003;10(2):84–6.
32.
go back to reference Moore D, et al. Low COVID-19 vaccine hesitancy in Brazil. Vaccine. 2021;39(42):6262–8.CrossRef Moore D, et al. Low COVID-19 vaccine hesitancy in Brazil. Vaccine. 2021;39(42):6262–8.CrossRef
33.
go back to reference Alabdulla M, et al. COVID-19 vaccine hesitancy and attitudes in Qatar: a national cross-sectional survey of a migrant-majority population. Influenza Other Respir Viruses. 2021;15(3):361–70.CrossRef Alabdulla M, et al. COVID-19 vaccine hesitancy and attitudes in Qatar: a national cross-sectional survey of a migrant-majority population. Influenza Other Respir Viruses. 2021;15(3):361–70.CrossRef
34.
go back to reference Altulaihi BA, et al. Factors and determinants for uptake of COVID-19 vaccine in a medical university in Riyadh, Saudi Arabia. Cureus. 2021;13(9): e17768. Altulaihi BA, et al. Factors and determinants for uptake of COVID-19 vaccine in a medical university in Riyadh, Saudi Arabia. Cureus. 2021;13(9): e17768.
35.
go back to reference Dudley MZ, Privor-Dumm L, Dubé È, MacDonald NE. Words matter: vaccine hesitancy, vaccine demand, vaccine confidence, herd immunity and mandatory vaccination. Vaccine. 2020;38(4):709–11.CrossRef Dudley MZ, Privor-Dumm L, Dubé È, MacDonald NE. Words matter: vaccine hesitancy, vaccine demand, vaccine confidence, herd immunity and mandatory vaccination. Vaccine. 2020;38(4):709–11.CrossRef
36.
go back to reference Olson O, Berry C, Kumar N. Addressing parental vaccine hesitancy towards childhood vaccines in the United States: a systematic literature review of communication interventions and strategies. Vaccines. 2020;8(4):1–25.CrossRef Olson O, Berry C, Kumar N. Addressing parental vaccine hesitancy towards childhood vaccines in the United States: a systematic literature review of communication interventions and strategies. Vaccines. 2020;8(4):1–25.CrossRef
37.
go back to reference Cataldi JR, O’Leary ST. Parental vaccine hesitancy: scope, causes, and potential responses. Curr Opin Infect Dis. 2021;34(5):519–26.CrossRef Cataldi JR, O’Leary ST. Parental vaccine hesitancy: scope, causes, and potential responses. Curr Opin Infect Dis. 2021;34(5):519–26.CrossRef
41.
go back to reference Du Y, Chen L, Shi Y. Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis. Front Public Health. 2022;10: 829176.CrossRef Du Y, Chen L, Shi Y. Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis. Front Public Health. 2022;10: 829176.CrossRef
43.
go back to reference Bsoul EA, Loomer PM. COVID-19 vaccination experience among United States dental professionals and students: safety, confidence, concerns, and side effects. PLoS ONE. 2022;17(2): e0264323.CrossRef Bsoul EA, Loomer PM. COVID-19 vaccination experience among United States dental professionals and students: safety, confidence, concerns, and side effects. PLoS ONE. 2022;17(2): e0264323.CrossRef
44.
go back to reference Leonard MB, et al. The importance of trustworthiness: lessons from the COVID-19 pandemic. Pediatr Res. 2022;91(3):482–5.CrossRef Leonard MB, et al. The importance of trustworthiness: lessons from the COVID-19 pandemic. Pediatr Res. 2022;91(3):482–5.CrossRef
Metadata
Title
COVID-19 vaccination side effects among the child age group: a large cross-sectional online based survey in Saudi Arabia
Authors
Hassan Alwafi
Abdallah Y. Naser
Abdulelah M. Aldhahir
Ahmad Alhazmi
Areen Naif Alosaimi
Rasha Abdulaziz Mandili
Zaid Majeed
Emad Salawati
Rakan Ekram
Mohammed Samannodi
Hamza Assaggaf
Mohammed Almatrafi
Jaber S. Alqahtani
Safaa Mohammed Alsanosi
Faisal Minshawi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07905-2

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.